Psychopharmacology

, Volume 94, Issue 3, pp 342–346

1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI) exerts an anorexic action that is blocked by 5-HT2 antagonists in rats

  • L. E. Schechter
  • K. J. Simansky
Original Investigations

Abstract

Previous literature suggests that the anorexic action of peripherally administered serotonin (5-HT) is mediated by 5-HT2 receptors. This study, therefore, examined the effect of DOI, a non-indole 5-HT2 agonist, on deprivation-induced feeding. Rats were first adapted to a schedule in which a milk diet was presented for 6 h daily. Intraperitoneal (IP) administration of DOI (1.0–11.2 μmol/kg) inhibited feeding in a dose-related fashion (ID50=2.6 μmol/kg). One hour pretreatment with 6.0 μmol/kg of the 5-HT2 antagonists ketanserin and LY53857 completely reversed the anorexic action of an equimolar dose of DOI. Neither ketanserin nor LY53857, alone, altered baseline feeding. Further testing demonstrated the antagonistic effect of LY53857 (0.047–6.0 μmol/kg, IP) to be dose related, with an ID50 of 0.14 μmol/kg. Ten minute pretreatment with 1-(1-naphthyl)-piperazine (1-NP; 2.0 or 4.0 μmol/kg), a mixed-acting agent with 5HT2 blocking actions, also attenuated the anorexic effect of 6.0 μmol/kg DOI. Unlike ketanserin and LY53857, however, 1-NP did reduce food intake by itself. By contrast with ketanserin, LY53857 and 1-NP, the peripherally-acting 5-HT2 antagonist xylamidine failed to alter the anorexic effect of DOI. Taken together, these results suggest that central 5-HT2 receptors are important in the control of ingestive behavior.

Key words

1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane DOI 5-HT2 receptors LY53857 1-(1-naphthyl)piperazine 1-NP Ketanserin Xylamidine Feeding 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bendotti C, Samanin R (1987) The role of putative 5-HT1a and 5-HT1b receptors in the control of feeding in rats. Life Sci 41:635–642Google Scholar
  2. Berken GH, Weinstein DO, Stern WC (1984) Weight gain — a side effect of tricyclic antidepressants. J Affective Disord 7:133–138Google Scholar
  3. Blackshear MA, Sanders-Bush E (1982) Serotonin receptor sensitivity after acute and chronic treatment with mianserin. J Pharmacol Exp Ther 221:303–308Google Scholar
  4. Blundell JE (1977) Is there a role for serotonin (5-hydroxytryptamine) in feeding? Int J Obes 1:15–42Google Scholar
  5. Clineschmidt BV, McGuffin JC, Pflueger AB, Totaro JA (1978) A 5-hydroxytryptamine-like mode of anorectic action for 6-chloro-2-{1-piperazinyl}-pyrazine (MK-212). Br J Pharmacol 62:579–589Google Scholar
  6. Clineschmidt BV, Reiss DR, Pettibone DJ, Robinson JL (1985) Characterization of 5-hydroxytryptamine receptors in rat stomach fundus. J Pharmacol Exp Ther 235(3):696–708Google Scholar
  7. Cohen ML, Fuller RW, Kurz KD (1983a) Evidence that blood pressure reduction by serotonin antagonists is related to alpha receptor blockade in spontaneously hypertensive rats. Hypertension 5(5):676–681Google Scholar
  8. Cohen ML, Fuller RW, Kurz KD (1983b) LY53857, a selective and potent serotonergic (5-HT2) receptor antagonist, does not lower blood pressure in the spontaneously hypertensive rat. J Pharmacol Exp Ther 227(2):327–332Google Scholar
  9. Cohen ML, Colbert W, Wittenauer LA (1985a) Receptor specificity of the 5-HT2 receptor antagonist, LY53857. Drug Dev Res 4:313–321Google Scholar
  10. Cohen ML, Schenck KW, Colbert W, Wittenauer L (1985b) Role of 5-HT2 receptors in serotonin-induced contractions of non-vascular smooth muscle. J Pharmacol Exp Ther 232(3):770–774Google Scholar
  11. Copp FC, Green AF, Hodson HF, Randall AW, Sim MF (1967) New peripheral antagonists of 5-hydroxytryptamine. Nature 214:200–201Google Scholar
  12. Dourish CT, Hutson PH, Kennett GA, Curzon G (1986) 8-OH-DPAT-induced hyperphagia: its neural basis and possible therapeutic relevance. Appetite [Suppl] 7:127–140Google Scholar
  13. Dwoskin LP, Sparber SB (1983) Behaviorally inactive doses of mianserin antagonize the suppressant effect of lysergic acid diethylamide on a fixed-ratio operant. J Pharmacol Exp Ther 225(1):77–84Google Scholar
  14. Fletcher PJ, Burton MJ (1986) Dissociation of the anorectic actions of 5-HTP and fenfluramine. Psychopharmacology 89:216–220Google Scholar
  15. Fuller RW, Snoddy HD, Mason NR, Hemrick-Luecke SK, Clemens JA (1981) Substituted piperazines as central serotonin agonists: Comparative specificity of the postsynaptic actions of quipazine and m-trifluoromethylphenylpiperazine. J Pharmacol Exp Ther 218(3):636–641Google Scholar
  16. Fuller RW, Kurz KD, Mason NR, Cohen ML (1986) Antagonism of a peripheral vascular but not an apparently central serotonergic response by xylamidine and BW 501C67. Eur J Pharmacol 125:71–77Google Scholar
  17. Glennon RA (1986) Discriminative stimulus properties of the serotonergic agent 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI). Life Sci 39:825–830Google Scholar
  18. Glennon RA, Titeler M, McKenney JD (1984) Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 35:2505–2511Google Scholar
  19. Glennon RA, Slusher RM, Lyon RA, Titeler M, McKenney JD (1986) 5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem 29:2375–2380Google Scholar
  20. Gudelsky GA, Koenig JI, Meltzer HY (1986) Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat. Evidence for opposing roles of 5-HT2 and 5-HT1A receptors. Neuropharmacology 25(12):1307–1313Google Scholar
  21. Harris B, Harper M (1980) Unusual appetites in patients on mianserin. Lancet I (8168):590Google Scholar
  22. Henck JW, Rezabek DH, Rech RH (1985) Comparison of anorexia and motor disruption by cyclazocine and quipazine. Pharmacol Biochem Behav 22:671–676Google Scholar
  23. Hoyer D, Engel G, Kalkman HO (1985) Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes: radioligand binding studies with [3H]5-HT, [3H]8-OH-DPAT, (-)[125I] iodocyanopindolol, [3H]mesulergine and [3H]ketanserin. Eur J Pharmacol 118:13–23Google Scholar
  24. Kirk RE (1982) Experimental design: procedures for the behavioral sciences. Brooks/Cole, Belmont, CAGoogle Scholar
  25. Leysen JE, Tollenaere JP (1982) Biochemical models for serotonin receptors. Annu Rep Med Chem 17:1–10Google Scholar
  26. Leysen JE, Niemeyeers CJE, Tollenaere JP, Laduron PM (1982) [3H]-ketanserin (R41468), a selective 3H-ligand for serotonin2 receptor binding sites. Mol Pharmacol 21:301–314Google Scholar
  27. Leibowitz SF, Shor-Posner G (1986) Brain serotonin and eating behavior. Appetite [Suppl] 7:1–14Google Scholar
  28. Lucki I, Nobler MS, Frazer A (1984) Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in rat. J Pharmacol Exp Ther 228(3):133–139Google Scholar
  29. Massi M, Marini S (1987) Effect of the 5-HT2 antagonist ritanserin on food intake and on 5-HT induced anorexia in the rat. Pharmacol Biochem Behav 26:333–340Google Scholar
  30. Mawson C, Whittington H (1970) Evaluation of the peripheral and central antagonistic activities against 5-hydroxytryptamine of some new agents. Br J Pharmacol 39:223PGoogle Scholar
  31. Mokler DJ, Commissaris RL, Warner MR, Rech RH (1983) Blockade of the behavioral effects of lysergic acid diethylamide, 2,5-dimethoxy-4-methylamphetamin, quipazine and lisuride by 5-hydroxytryptamine antagonists. J Pharmacol Exp Ther 227(3):557–562Google Scholar
  32. Mokler DJ, Stoudt KW, Rech RH (1985) The 5-HT2 antagonist pirenperone reverses disruption of FR-40 by hallucinogenic drugs. Pharmacol Biochem Behav 22:677–682Google Scholar
  33. Nobrega JN, Coscina DV (1987) Effects on chronic amitriptyline and desipramine on food intake and body weight in rats. Pharmacol Biochem Behav 27:105–112Google Scholar
  34. Peroutka SJ (1986) Pharmacological differentiation and characterization of 5-HT1A, 5-HT1B, and 5-HT1C binding sites in rat frontal cortex. J Neurochem 47:529–540Google Scholar
  35. Peroutka SJ, Snyder SH (1980) Long-term antidepressant treatment decreases spiroperidol labelled serotonin receptor binding. Science 210:88–90Google Scholar
  36. Rech RH, Commissaris RL (1982) Neurotransmitter basis of the behavioral effects of hallucinogens. Neurosci Biobehav Rev 6:521–527Google Scholar
  37. Samanin R, Bendotti C, Candelaresi G, Garattini S (1977) Specificity of serotonergic involvement in the decrease of food intake induced by quipazine in the rat. Life Sci 21:1259–1266Google Scholar
  38. Samanin R, Mennini T, Ferraris A, Bendotti C, Borsini F, Garattini S (1979) m-Chlorophenylpiperazine: a central serotonin agonist causing powerful anorexia in rats. Naunyn-Schmiedeberg's Arch Pharmacol 308:159–163Google Scholar
  39. Shannon M, Battaglia G, Glennon RA, Titeler M (1984) 5-HT1 and 5-HT2 binding properties of derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane (2,5-DMA). Eur J Pharmacol 102:23–29Google Scholar
  40. Simansky KJ, Schechter LE (1987) Dissociation of behavioral properties of 1-arylpiperazines in models for central serotonergic stimulation in rodents. Fed Proc [Abstr] 46:966Google Scholar
  41. Simansky KJ, Bourbonais KA, Smith GP (1985) Food-related stimuli increase the ratio of 3,4-dihydroxyphenylacetic acid to dopamine in the hypothalamus. Pharmacol Biochem Behav 23:253–258Google Scholar
  42. Simansky KJ, Cohen BI, Eberle K (1987) Inhibition by 5-HT2 antagonists of the anorexic actions of peripherally administered 5-hydroxytryptamine (5-HT) and 4-HT in rats. Soc Neurosci [Abstr] 13:15Google Scholar
  43. Standridge RT, Howell HG, Gylys JA, Partyka RA (1976) Phenylalkylamines with potential psychotherapeutic utility. 1. 2-amino-1-(2,5-dimethoxy-4-methylphenyl)butane. J Med Chem 19(12):1400–1404Google Scholar
  44. Tallarida RJ, Murray RB (1981) Manual of pharmacologic calculations with computer programs. Springer, New YorkGoogle Scholar
  45. Tricklebank MD, Forler C, Fozard JR (1985a) The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioral response to 8-hydroxy-2-(di-n-propylamino) tetralin in the rat. Eur J Pharmacol 106:271–282Google Scholar
  46. Tricklebank MD, Forler C, Middlemiss DN, Fozard JR (1985b) Subtypes of the 5-HT receptor mediating the behavioral responses to 5-methoxy-N,N-dimethyltryptamine in the rat. Eur J Pharmacol 117:15–24Google Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • L. E. Schechter
    • 1
  • K. J. Simansky
    • 1
  1. 1.Department of PharmacologyMedical College of Pennsylvania at Eastern Pennsylvania Psychiatric InstitutePhiladelphiaUSA

Personalised recommendations